Sensory gating is the brain's ability to filter out irrelevant information before it reaches high levels of conscious processing. In the current study we aimed to investigate the involvement of the noradrenergic and dopaminergic neurotransmitter systems in sensory gating. Furthermore, we investigated cross-species reliability by comparing effects in both healthy humans and rats, while keeping all experimental conditions as similar as possible between the species. The design of the human experiment (n = 21) was a double-blind, placebocontrolled, cross-over study where sensory gating was assessed following a dose of either reboxetine (8 mg), haloperidol (2 mg), their combination or placebo at four separate visits. Similarly in the animal experiment sensory gating was assessed in rats, (n = 22) following a dose of reboxetine (2 mg/kg), haloperidol (0.08 mg/kg), their combination or placebo. The sensory gating paradigms in both experiments were identical. In humans, we found significantly reduced P50 suppression following separate administration of reboxetine or haloperidol, while their combined administration did not reach statistical significance compared with placebo. In the rats, we found a similar significant reduction of sensory gating (N40) following treatment with haloperidol and the combination of haloperidol and reboxetine, but not with separate reboxetine treatment, compared with placebo. Our study indicates that even when experimental conditions are kept as similar as possible, direct human to rat cross-species translation of pharmacological effects on sensory gating is challenging, which calls for more focussed research in this important translational area.
INTRODUCTION
Humans, and many other species, are constantly subjected to stimuli and impressions from their surroundings. Although the brain is a multifaceted organ, it cannot possibly attend to all of these stimuli and therefore filtering mechanisms have evolved to help ensure that only relevant information reaches the higher brain functions. One way believed to assess the brain's ability to suppress irrelevant incoming information, commonly referred to as sensory gating, is to subject an individual to a, so-called, P50 suppression paradigm: in a typical paradigm, two identical auditory stimuli are presented in close temporal proximity (usually 500 ms). In healthy humans the brain's response to the second (testing) stimulus is normally reduced compared with its response to the first (conditioning) stimulus, usually assessed with electroencephalography (EEG; reviewed by Light and Braff, 1999) . In humans, it is mainly the P50 event-related potential (ERP, a positive deflection seen in the EEG~50 ms after a response-eliciting stimulus) also sometimes referred to as the P1 amplitude that is scored to express sensory gating (Chang et al, 2011) . However, in addition the succeeding N100 (or N1, a negative ERP at 100 ms) and P200 (or P2) have been used to assess sensory gating (Boutros et al, 1999) , although there is different underlying neural activity involved (Boutros et al, 2004; Brockhaus-Dumke et al, 2008; Oranje et al, 2006) . Similar to humans, other animal species such as primates, cats, rabbits, rats, and mice display sensory gating. The rat equivalent of the human P50 has been subjected to much scrutiny; while some believe it to be the P13 (P1; Miyazato et al, 1999) others believe it to be the N40 (N1; Mears et al, 2006) . The discussion may be related to the fact that the pattern of rat ERPs elicited by a simple auditory stimulus is remarkably similar to that in humans, with more or less the only exception being that the ERP latencies are~60% shorter than those in humans (Adler et al, 1982; Siegel et al, 2003) .
Extensive research has shown disrupted P50 gating in patients with schizophrenia compared with healthy controls, whether patients were medicated (Adler et al, 1982; Bramon et al, 2004; Nagamoto et al, 1989) or antipsychotic naive, first episode patients (Brockhaus-Dumke et al, 2008; Oranje et al, 2013) . Similarly, deficits in N1 gating have been reported in schizophrenic patients compared with healthy controls (Boutros et al, 1999; Brockhaus-Dumke et al, 2008) . It should be noted however, that it is difficult to interpret the consequences of deficient P50 suppression in patients with schizophrenia, since not all patients with low P50 gating show perceptual anomalies (Jin et al, 1998) .
Evidence is accumulating for involvement of dopaminergic (eg, Csomor et al, 2008; Oranje et al, 2002) as well as noradrenergic (eg, Adler et al, 1994; Baker et al, 1990; Hammer et al, 2007) neurotransmission in healthy sensory gating. In addition, in a recent clinical study from our laboratory, we showed that the specific noradrenergic α2-agonist clonidine alleviated sensory-as well as sensorimotor gating deficits in schizophrenia patients (Oranje and Glenthoj, 2013a, b) .
Given all of the above, the current study was designed to first determine the equivalents of human P50 gating in rats, and to investigate whether these rat equivalents would respond in the same way to pharmacological challenges as human P50 gating does. Finding the correct equivalents of human P50 gating in rats is important because it may facilitate translational research and drug development in schizophrenia. The pharmacological challenges consisted of the specific noradrenaline reuptake inhibitor reboxetine and the antipsychotic haloperidol (predominantly a dopaminergic-D2 receptor antagonist), both administered separately, as well as combined. The hypothesis was that all three pharmacological challenges would disrupt gating in both species.
MATERIALS AND METHODS

General
The human study was approved by the Ethics committee (H-3-2010-098) of the Capital region, Copenhagen, with regard to the ethical principles for medical research involving human subjects as stated in the Declaration of Helsinki Principles (amendment of Washington, 2002) . Similarly, the animal study was carried out in accordance with the European Communities Council Directive (86/609/EEC) for the care and use of laboratory animals and the Danish legislation regulating animal experiments. The Danish Animal Experimentation Inspectorate approved the protocols (journal no. 2004/561-798 and 2009/561-1596) .
Human Study
Subjects. Twenty-one healthy male volunteers recruited from the capital region of Copenhagen through the web page www.forsøgsperson.dk participated in the study. Written informed consent was obtained from all subjects before enrolment, following written and oral information on the project.
All subjects were aged between 18-30 years, mean age was 23.4 years (SD = 2.8), mean weight was 78.5 kg (SD = 7.7), while mean height was 185 cm (SD = 8.9), resulting in a mean BMI of 22.9 (SD = 1.8). Of the 21 recruited participants, 4 were tobacco smokers. Mental health history and absence of a history of drug and alcohol abuse were ascertained by the use of the Schedule for Clinical Assessment in Neuropsychiatry, version 2.0 (Wing et al, 1990) . Furthermore, an electrocardiogram was taken prior to the participation in the experiment to ensure healthy heart function. Exclusion criteria were the use of current medication, history of neurological or psychiatric illness, psychiatric illness in a first degree relative, alcohol or drug abuse, and previous participation in a psychophysiological assessment. Urine samples were taken at each visit to test for the absence of opiates, cocaine, amphetamine, and cannabis. Finally, it was ascertained that the volunteers were free of hearing deficits (at frequencies of 500, 1000, and 6000 Hz and intensities of 20 and 40 dB).
Design and treatment. The design of the experiment was a double-blind, placebo-controlled, cross-over study, where an oral dose of 8 mg reboxetine (Edronax, Pfizer), 2 mg haloperidol (Serenase, Janssen), their combination or placebo (folic acid and/or C-vitamin) was administered to the 21 participants at four separate visits with a minimum of 2 weeks apart (to allow washout of the compounds). The dosages were chosen based on the guidelines for clinical treatment of first users (Kapur et al, 2000b; Preskorn, 2004) . Previous studies have shown that peak plasma level of haloperidol is reached after 2-6 h following administration, while its terminal half-life is~24 h (Huang et al, 1996) . For reboxetine, the maximum plasma level is reached within 2 h following oral intake, while its terminal half-life is~13 h (Hajos et al, 2004) .
During each of the sessions, blood samples were taken from the subjects just before and immediately after the psychophysiological assessments to evaluate the plasma levels of the compounds in retrospective analysis. Furthermore, blood pressure was recorded and psychometric ratings of alertness were assessed with a visual analog scale (Bond, 1974) at fixed time intervals (see below).
The subjects arrived at the Center for Neuropsychiatric Schizophrenia Research, Glostrup academic hospital, at 09:00. They had been requested to fast from 23:00 of the preceding night and to abstain from caffeinated beverages 2 h before and from cigarette smoking 1 h before the psychophysiological assessments. This, in order to avoid effects of food intake on the pharmacokinetics of the compounds as well as to avoid acute or withdrawal effects of nicotine and caffeine. In addition, participants were requested not to consume any alcohol on the preceding day. The active compounds or placebo were administered orally in a white opaque capsule and subjects were requested to wait for 120 min to allow the compounds to reach maximal plasma levels (see above). Thereafter the subjects were tested in the Copenhagen Psychophysiological Test Battery, which consists of PPI, P50 suppression, mismatch negativity, and selective attention paradigms presented in that order (for more details see: Oranje and Glenthoj, 2013c; Jensen et al, 2008; Wienberg et al, 2010 ). In the current paper, only results on P50 suppression will be reported.
Animal Study
Animals. Male, Lister-Hooded rats (Charles River, The Netherlands) were used in all experiments.
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Housing consisted of a transparent, high, grid-lid macrolon cage, type III or IV (type IV GH; 54 × 36 × 18 cm; type III IR; 37 × 22 × 18 cm), with wood-chip bedding and environmental enrichment (plastic house and wooden chew blocks). All animals were housed under controlled temperature (20 ± 2°C) and humidity conditions (30-70%) with a reversed 12 : 12 h light/dark cycle. Food and water were available ad libitum.
Treatment. Reboxetine (Abcam, Cambridge, UK) was dissolved in isotonic, slightly warmed water and haloperidol (Sigma-Aldrich, St Louis, MO, USA) was dissolved in saline to which a small amount of tartaric acid was added (pH 5.5). The dosages administered in the rat study were carefully chosen in such a way that they were equivalent to the human dosages with respect to unbound peak plasma concentrations (reboxetine) and D2 occupancy (haloperidol). For haloperidol the rat equivalent of the human 2 mg dose was 0.08 mg/ kg, for reboxetine the rat equivalent of the human 8 mg dose was 2 mg/kg reboxetine administered s.c. (see Supplementary Materials for more details).
Human and Rat Gating Paradigms and Data Processing
The human gating paradigm as well as its processing and assessment have been previously described (Oranje et al, 2013; Oranje and Glenthoj, 2013a) . Similarly, the rat gating paradigm as well as its assessment and processing have been described before (Broberg et al, 2010; Witten et al, 2014) with the exception that the coordinates for electrode placement in the current rat study were: frontal cortex (+3.0 mm anterior, − 0.5 mm lateral), ground (−4.5 mm posterior, +4.0 lateral) and a depth electrode in CA-3 region of the hippocampus (−5.2 mm posterior to bregma, − 5.0 mm lateral, − 4.8 mm ventral to dura). Further changes to the gating paradigm in rats include a low pass-filter setting of 300 Hz in the recording session and 1.5 ms duration (instantaneous rise and fall time) of clicks. Please see the Supplementary Materials for more details.
Statistical Analysis
Statistical analysis was performed with SPSS (version 11.0; SPSS) for human data and SigmaPlot (version 11.0) for rat data. The human and rat data were normally distributed (Kolmogorov-Smirnov). The raw amplitudes of P50, N100, P1, and N1 were analyzed with two-way repeated measures analysis of variance (ANOVA), with within-factors 'treatment' (the four different treatments) and 'stimulus' (C or T) to find out whether suppression occurred and to see whether treatment had an effect on raw amplitude. The suppression data (T/C ratio) were analyzed with a one-way repeated measures ANOVA with the factor treatment to study the effect of treatment on P50, N100, P1, and N1 gating. In cases where the ANOVAs indicated statistical significance, post hoc Tukey tests were performed. Outlying values exceeding the mean by two SD were Winsorized (truncated) to values corresponding to 2 SD from the mean (Dixon and Tukey, 1968) .
In the animal data set one animal had to be excluded from the full analysis because the ERPs from the placebo treatment were missing. Furthermore, one data set was lost due to hardware problems.
In general, data are expressed as group mean ± SEM unless otherwise stated. A p-value of o0.05 was regarded as statistically significant (po0.05).
RESULTS
Humans
P50.
On raw amplitude level, the repeated-measures ANO-VA showed a main effect of stimulus (F(1, 20) = 85.37, po0.001; Figures 1 and 2 ; Table 1 ), indicating that the subjects' average amplitude to T-stimuli were significantly lower than that to C-stimuli, thus confirming that the paradigm performed as intended. Neither a main effect of treatment (F(3, 18) = 0.52, p = 0.672) nor a stimulus by treatment Figure 1 Grand averages of the auditory-evoked potentials in healthy human subjects. (a) Placebo/placebo and reboxetine/placebo, (b) placebo/ placebo and haloperidol/placebo, (c) placebo/placebo and haloperidol/ reboxetine.
Effects of haloperidol and reboxetine on sensory gating L Witten et al interaction effect (F(3, 60) = 0.92, p = 0.437) were found (see Figure 3a ). In the suppression data (T/C ratio) repeated-measures ANOVA revealed a main effect of treatment (F(3, 18) = 5.00, p = 0.011). Further analysis (post hoc Tukey's tests) revealed that the T/C ratio of haloperidol/placebo (p = 0.032) and reboxetine/placebo (p = 0.046) treatments were significantly higher than in the placebo/placebo treatment, while the increased ratio in the haloperidol/reboxetine did not reach statistical significance (p = 0.103) compared with placebo/ placebo (see Figure 4a ). N100. Repeated-measures ANOVA showed a main effect of stimulus (F(1, 20) = 23.04, po0.001), indicating that the subjects' average amplitude to T-stimuli were significantly lower than to C-stimuli. Neither a main effect of treatment (F(3, 20) = 2.25, p = 0.91) nor stimulus by treatment interaction effect (F(3, 60) = 1.17, p = 0.329) were found on raw amplitude level. No significant treatment effects were found for the T/C ratio of the N100 (F(3, 18) = 1.252, p = 0.320; see Figures 3a and 4a) .
Rats
Hippocampus P1. On raw amplitude level, a main effect of stimulus (F(1, 19) = 8.22, p = 0.010) was found, showing that the subjects' average amplitude to T-stimuli were significantly lower than to C-stimuli. Neither a main effect of treatment (F(3, 19) = 0.48, p = 0.698) nor stimulus by treatment interaction effect (F(3, 57) = 0.27, p = 0.848) were found. No significant treatment effects were found (F(3, 17) = 0.26, p = 0.878) in the T/C ratio of P1 (see Figures 3b and 4b ).
N1.
On raw amplitude level, a main effect of stimulus (F(1, 19) = 88.44, po0.001) was found, showing that the subjects' average amplitude to T-stimuli were significantly lower than that to C-stimuli, therewith confirming that the paradigm worked as intended. Neither a main effect of treatment (F(3, 19) = 1.06, p = 0.375) nor a stimulus by treatment interaction effect (F(3, 57) = 1.76, p = 0.166) were found (see Figure 3b) .
Repeated-measures ANOVA on the T/C ratios revealed a significant effect of treatment (F(3, 17) = 10.16, po0.001). Further analysis (post hoc Tukey's tests) revealed that the T/C ratio in haloperidol/placebo (po0.001) and haloperidol/ reboxetine (p = 0.005) treatments were significantly higher than in the placebo/placebo treatment, but the reboxetine/ placebo treatment was not significantly different (p40.05; see Figure 4b ).
Latencies. No significant treatment differences in the latencies of the above mentioned ERPs were found in either rats or humans (data not shown).
DISCUSSION
In the current study, we tested the effects of reboxetine, haloperidol, and their combination on auditory sensory gating in healthy male humans and rats. Whereas all three active treatments reduced P50 gating in healthy males compared with placebo, this only reached statistical significance in the case of the separate reboxetine and haloperidol treatments. No significant effect of treatment was found on human N100 gating compared with placebo. In rats, haloperidol and the combination of haloperidol and reboxetine Our finding that reboxetine has a disruptive effect on P50 gating in healthy males is in alignment with previous studies investigating the effect of increased NE activity in healthy volunteers such as the effect of yohimbine (Adler et al, 1994) or imipramine (Hammer et al, 2007) . As reboxetine is a selective blocker of NET in humans and rats (Hajos et al, 2004) , its disruptive effect on human P50 gating supports involvement of the NE system in sensory gating. However, in rats we found no effects of reboxetine. A previous study investigating the effects of yohimbine (selective α-2 noradrenergic antagonist) reported disrupted gating in rats (Stevens et al, 1993) , indicating that also in rats increased NE activity can lead to impaired gating. Our negative finding may be explained by the fact that we calculated the rat dose of reboxetine from our human plasma levels: we have, therefore, no information on how the human and rat doses relate to receptor occupancy in the brain.
Haloperidol disrupted P50 gating in our human subjects compared with placebo treatment. Although there are many studies showing that haloperidol and the other typical antipsychotics do not seem to influence disrupted sensory gating in patients with schizophrenia (Adler et al, 2004; Arango et al, 2003; Becker et al, 2004) , only a few studies investigated healthy human subjects on this matter. A previous study from our laboratory somewhat supports that haloperidol disrupts gating in healthy humans (Oranje et al, 2002) . In another study, haloperidol increased P50 suppression in subjects exhibiting low levels of P50 gating yet disrupted it in subjects expressing high levels (Csomor et al, 2008) , indicating that blocking dopamine-D2 receptors affect sensory gating in healthy humans. Considering these two studies and the fact that healthy males usually score high levels of P50 gating, it may explain why we, in the current study, find that haloperidol reduced average P50 gating. Therefore, although other recent data from our lab showed that P50 suppression deficits are already present in Figure 3 Individual peak amplitudes for P1 and N1 ± SEM of (a) humans and (b) rats (hippocampus) (Cz). P = placebo/placebo, R = reboxetine/ placebo, H = haloperidol/placebo, RH = reboxetine/haloperidol.
Effects of haloperidol and reboxetine on sensory gating L Witten et al antipsychotic naive, first-episode patients with schizophrenia (eg, Oranje et al, 2013) , our current data raise the possibility that D2 antagonism may contribute to the P50 suppression deficits reported from studies on medicated patients with schizophrenia. Similar to our human P50 gating data, haloperidol disrupted gating (N1) in the hippocampus of rats.
In previous animal studies, haloperidol is mainly used in gating experiments to antagonise the disruptive effects of, eg, amphetamine, phencyclidine, and morphine (Adler et al, 1986; Zheng et al, 2005) . The few studies that have investigated haloperidol's effect alone have shown either no effect (Ma et al, 2009) or improved gating (Anstrom et al, 2007) with administration of 1 mg/kg haloperidol using intraperitoneal or intramuscular injections, respectively. As this dose of haloperidol has been found to result in a D2 occupancy level above 80%, which may induce extrapyramidal side effects such as catalepsy (Kapur et al, 2000a) , comparison between studies remains difficult.
Given that the compounds administered separately significantly disrupted P50 gating in our human volunteers, it was surprising to find that the combination did not significantly affect their gating levels. This indicates that the combination of compounds does not have a synergistic or additive effect. This can be due to a simple power issue of the study or it may be that a pharmacodynamic interaction is involved in this discrepancy. For instance, it has been shown that haloperidol significantly reduces baseline levels of NE in rats (Amato et al, 2011) . A growing body of evidence has indicated that an optimal functional PFC is essential for normal levels of gating (Bak et al, 2011; Oranje et al, 2006 Oranje et al, , 2013 Weisser et al, 2001) . Interestingly, there is no dopamine transporter in the rat PFC, nor in humans as a matter of fact: dopamine in the PFC is removed by NET (Carboni et al, 1990; Pozzi et al, 1994) . Given this, it may be that the two compounds counterbalance each other's action in the PFC. In contrast, in rats we actually did find a significant reduction of (N1) gating with administration of reboxetine and haloperidol. However, as we found no significant effect of separate reboxetine treatment this may indicate that the observed disruption is solely due to the effect of haloperidol suggesting that the theorized human counterbalance effect from the two compounds is not evident in rats. Figure 4 T/C ratio (± SEM) of placebo/placebo, reboxetine/placebo, haloperidol/placebo and reboxetine/haloperidol in P1/P50 and N1/N100 of (a) humans showing significantly increased T/C ratio in the reboxetine/placebo and haloperidol/placebo treatments compared with placebo/placebo and (b) rats (hippocampus) showing significant increased T/C ratio of N1 gating with haloperidol/placebo and haloperidol/reboxetine treatment compared with placebo/placebo. *Po0.05.
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When back-translating the human results to the rat there are certain things to take into consideration. These include that the pattern of rat ERPs in our P50 suppression paradigm displays remarkable similarities with that of humans. Therefore, one would expect the P50 peak in humans to be equivalent to the P13 in rats, whereas the human N100 would be equivalent to the rat N40. However, in human studies mainly P50 suppression is reported, while in rats mainly N40 gating is observed, which is in line with what we find in the current study, where pharmacological disruption occurred of human P50 and rat N40. Speculatively, it may be that the shorter latencies of the rat ERPs compared with the human ERPs make the expression of gating occur at a later latency in the rat EEG than in the human EEG.
In rats, we had additional recording electrodes placed on the skull to record cortical activity, besides having inserted a depth electrode in the CA3 area of the hippocampus. Nevertheless, it was only at the hippocampal site that we obtained a significant treatment effect on gating (see Supplementary Material for cortical data). The signals recorded from the hippocampus might be more 'pure' in the sense that one avoids the noise generated in other areas of the brain that could have been picked up by the large low impedance surface screw electrodes. Another explanation may come from the accumulating evidence for a role of the hippocampus, beside that of the PFC, in the inhibitory processes underlying P50 suppression (Bak et al, 2011; Miller and Freedman, 1995) , which might explain why our treatment effect was mostly evident in this area. Nevertheless, this lack of direct cortical to cortical back-translation calls for a more detailed investigation of the translational value of sensory gating in human-to-rat studies.
There are strengths but also limitations to the current study. An obvious strength is that we, in contrast to many other studies, made a serious attempt to keep the experimental conditions between our human and rat studies as identical as possible, ie, we used identical paradigms and tried to reach identical plasma levels of the active compounds in both species. In spite of our efforts, however, there are of course factors that were not possible to change: rats were able to move freely, whereas the humans were instructed to sit still in a chair. As excitatory neurons in the auditory cortex of behaving mice have been shown to be suppressed before and during movement (Schneider et al, 2014) this may also have influenced our data. A further limitation may be that we have only investigated acute doses of the compounds, from which it is difficult to predict the effects of chronic treatment of the compounds, such as usually is the case in clinical settings. In conclusion, our data show that haloperidol disrupts gating in human cortex and rat hippocampus, while reboxetine only disrupts gating in humans but not in rats. The combination of the two compounds had no significant effect on human gating, while it significantly reduced gating in rats. Our study indicates that even when experimental conditions are kept as similar as possible, direct cross-species translation of pharmacological effects on sensory gating can only be marginally established, which calls for more focussed research in this important translational area.
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